Chiasma (NASDAQ:CHMA) Earning Somewhat Favorable Media Coverage, Study Shows
Media coverage about Chiasma (NASDAQ:CHMA) has trended somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chiasma earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.746025670961 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Chiasma (CHMA) traded down 3.33% during trading on Tuesday, hitting $1.45. The company had a trading volume of 14,306 shares. The stock has a 50-day moving average of $1.43 and a 200 day moving average of $1.59. Chiasma has a one year low of $1.25 and a one year high of $3.71. The company’s market capitalization is $35.32 million.
Chiasma (NASDAQ:CHMA) last released its earnings results on Friday, May 5th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.06. Equities analysts forecast that Chiasma will post ($0.96) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/09/chiasma-nasdaqchma-earning-somewhat-favorable-media-coverage-study-shows.html.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Receive News & Stock Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related stocks with our FREE daily email newsletter.